As patritumab-dxd's problems mount, Astra's decision to say no to this project looks smart.

But camizestrant’s use could depend on uptake of monitoring – for now.

DZD8586 shows some evidence that it can rescue BTK failures, but its precise role remains unclear.

Early data on SSGJ-707 in PD-L1-positive lung cancer spur comparisons against ivonescimab.

Any hopes of differentiation could come down to side effects.

Gilead’s TROP2 ADC sets the bar for Astra/Daiichi’s Datroway in first-line TNBC.